NEW YORK (Reuters Health) Jul 31 –
The biopharmaceutical firm Aphton Corp. said Wednesday that interim analysis of a phase II trial of the company’s anti-gastrin G17DT immunogen plus chemotherapy showed that 37 of 72 evaluable stomach cancer patients (51.4%) experienced a tumor response.
One of the patients in the study experienced a complete and 36 demonstrated partial responses. Investigators also reported an additional 20 of the chemotherapy-na ve patients had achieved stable disease. The chemotherapy regimen in the phase II trial consists of cisplatin and 5FU.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!